|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SEPP1 |
Gene summary for SEPP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SEPP1 | Gene ID | 6414 |
| Gene name | selenoprotein P | |
| Gene Alias | SELP | |
| Cytomap | 5p12 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P49908 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6414 | SEPP1 | Pt13.a | Human | Liver | HCC | 5.24e-18 | 5.07e-01 | 0.021 |
| 6414 | SEPP1 | Pt13.b | Human | Liver | HCC | 3.25e-42 | 3.21e-01 | 0.0251 |
| 6414 | SEPP1 | Pt13.c | Human | Liver | HCC | 9.74e-05 | 4.22e-01 | 0.0076 |
| 6414 | SEPP1 | Pt14.a | Human | Liver | HCC | 1.08e-07 | 1.37e-01 | 0.0169 |
| 6414 | SEPP1 | Pt14.b | Human | Liver | HCC | 6.43e-12 | 1.98e-01 | 0.018 |
| 6414 | SEPP1 | Pt14.d | Human | Liver | HCC | 5.17e-18 | 4.78e-01 | 0.0143 |
| 6414 | SEPP1 | S014 | Human | Liver | HCC | 5.98e-40 | -1.16e+00 | 0.2254 |
| 6414 | SEPP1 | S015 | Human | Liver | HCC | 1.19e-29 | -1.16e+00 | 0.2375 |
| 6414 | SEPP1 | S016 | Human | Liver | HCC | 1.42e-48 | -1.16e+00 | 0.2243 |
| 6414 | SEPP1 | S027 | Human | Liver | HCC | 2.22e-12 | -1.16e+00 | 0.2446 |
| 6414 | SEPP1 | S028 | Human | Liver | HCC | 1.17e-32 | -1.16e+00 | 0.2503 |
| 6414 | SEPP1 | S029 | Human | Liver | HCC | 7.04e-29 | -1.16e+00 | 0.2581 |
| 6414 | SEPP1 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 3.37e-06 | -1.12e+00 | -0.2116 |
| 6414 | SEPP1 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 1.92e-03 | -1.12e+00 | -0.2107 |
| 6414 | SEPP1 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 6.20e-05 | -1.12e+00 | -0.2119 |
| 6414 | SEPP1 | RNA-P3T-P3T-1 | Human | Lung | IAC | 3.37e-06 | -1.12e+00 | 0.1829 |
| 6414 | SEPP1 | RNA-P3T-P3T-2 | Human | Lung | IAC | 9.90e-07 | -1.12e+00 | 0.1835 |
| 6414 | SEPP1 | RNA-P3T-P3T-4 | Human | Lung | IAC | 4.41e-07 | -1.12e+00 | 0.1859 |
| 6414 | SEPP1 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 2.27e-21 | -1.12e+00 | -0.0166 |
| 6414 | SEPP1 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 1.40e-20 | -1.12e+00 | -0.0132 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |